Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 5/20 | 0.45 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.45 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.41 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 4/20 | 0.41 |
| ▸ | PLK1 | P53350 | 2/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.37 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | CDK9 | P50750 | 1/20 | 0.37 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20581833 | 0.89 | SRD5A1 (0.45) | TLR9TLR7SRD5A1SRD5A2ATM | |
| SCHEMBL20581146 | 0.87 | TLR9 (0.47) | TLR9TLR7SRD5A1SRD5A2PLK1 | |
| SCHEMBL20580566 | 0.87 | TLR9 (0.47) | TLR9TLR7SRD5A1SRD5A2PLK1 | |
| SCHEMBL20581181 | 0.86 | TLR9 (0.44) | TLR9TLR7SRD5A1SRD5A2PLK1 | |
| SCHEMBL20580802 | 0.86 | TLR9 (0.47) | TLR9TLR7SRD5A1SRD5A2PLK1 | |
| SCHEMBL20580553 | 0.86 | PDPK1 (0.46) | TLR9TLR7SRD5A1SRD5A2 | |
| SCHEMBL20580706 | 0.86 | NR1H2 (0.38) | TLR9ATMNR1H2 | |
| SCHEMBL20580555 | 0.85 | TLR9 (0.42) | TLR9TLR7SRD5A1SRD5A2PLK1 | |
| SCHEMBL20580573 | 0.84 | TLR9 (0.46) | TLR9TLR7SRD5A1SRD5A2PLK1 | |
| SCHEMBL20581147 | 0.84 | TLR9 (0.47) | TLR9TLR7CCNT1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3634962-B1 | AZAINDOLE COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-05-24 | — | — | EP | disclosed |
| US-20210371417-A1 | AZAINDOLE COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2021-12-02 | — | — | US | disclosed |
| US-11111243-B2 | Azaindole compounds as histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2021-09-07 | — | — | US | disclosed |
| CN-110997671-A | Azaindole compounds as histone methyltransferase inhibitors | 全球血液疗法股份有限公司 | 2020-04-10 | — | — | CN | disclosed |
| US-20180354947-A1 | AZAINDOLE COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2018-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11111243-B2 | Azaindole compounds as histone methyltransferase inhibitors | EHMT2, EHMT1, EZH2 | TLR9 3921/4885TLR7 4680/4885SRD5A1 3955/4885 |
| US-20210371417-A1 | AZAINDOLE COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | EHMT2, EHMT1, EZH2 | TLR9 3921/4885TLR7 4680/4885SRD5A1 3955/4885 |
| US-20180354947-A1 | AZAINDOLE COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | EHMT2, EHMT1, EZH2 | TLR9 3921/4885TLR7 4680/4885SRD5A1 3955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.